Aaron Cowen Suvretta Capital Management
Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Home Depot
HD
|
+$38M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
+$36.3M |
| 3 |
ETNB
89bio
ETNB
|
+$36.1M |
| 4 |
Bank of America
BAC
|
+$33.6M |
| 5 |
Chipotle Mexican Grill
CMG
|
+$29.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$92M |
| 2 |
Coca-Cola
KO
|
+$48.2M |
| 3 |
Starbucks
SBUX
|
+$47M |
| 4 |
CRH
CRH
|
+$41.5M |
| 5 |
McDonald's
MCD
|
+$30M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.02% |
| 2 | Technology | 10.47% |
| 3 | Consumer Discretionary | 6.61% |
| 4 | Financials | 5.33% |
| 5 | Communication Services | 4.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Mettler-Toledo International
MTD
$28B
| $2.32M | 0.09% |
1,964
| – | – |
|
77
Medtronic
MDT
$119B
| $2.25M | 0.08% |
25,060
+7,600
| +44% | +$680K |
|
78
Stryker
SYK
$126B
| $2.18M | 0.08% |
5,860
+1,500
| +34% | +$571K |
|
79
DexCom
DXCM
$34.8B
| $2.16M | 0.08% |
31,680
| – | – |
|
80
Trevi Therapeutics
TRVI
$2.56B
| $2.14M | 0.08% |
+340,164
| New | +$1.62M |
|
81
Natera
NTRA
$47.9B
| $1.43M | 0.05% |
10,100
| – | – |
|
82
Oric Pharmaceuticals
ORIC
$1.47B
| $1.42M | 0.05% |
+255,000
| New | +$2.23M |
|
83
IQVIA
IQV
$42.8B
| $1.26M | 0.05% |
7,175
| – | – |
|
|
84
CRH
CRH
$63.2B
| $1.24M | 0.05% |
14,050
-422,344
| -97% | -$41.5M |
|
85
McKesson
MCK
$100B
| $1.23M | 0.05% |
1,830
| – | – |
|
86
Elevance Health
ELV
$86.9B
| $1.19M | 0.04% |
2,740
| – | – |
|
87
Avantor
AVTR
$9.78B
| $1.16M | 0.04% |
71,850
| – | – |
|
88
Waters Corp
WAT
$40.4B
| $1.16M | 0.04% |
3,150
| – | – |
|
89
Sarepta Therapeutics
SRPT
$1.98B
| $1.14M | 0.04% |
17,888
| – | – |
|
90
HCA Healthcare
HCA
$92.9B
| $1.1M | 0.04% |
3,190
| – | – |
|
|
LKFT
91
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
| $932K | 0.03% |
37,111
| – | – |
|
92
Edwards Lifesciences
EW
$51.8B
| $805K | 0.03% |
11,100
| – | – |
|
93
Agilent Technologies
A
$44.9B
| $584K | 0.02% |
4,990
| – | – |
|
94
ResMed
RMD
$33.4B
| $535K | 0.02% |
2,390
| – | – |
|
95
Veralto
VLTO
$24.1B
| $534K | 0.02% |
5,475
| – | – |
|
96
Zimmer Biomet
ZBH
$19.3B
| $369K | 0.01% |
3,260
| – | – |
|
97
Steris
STE
$23.2B
| $347K | 0.01% |
1,530
| – | – |
|
98
Ionis Pharmaceuticals
IONS
$9.93B
| $326K | 0.01% |
10,800
| – | – |
|
99
Baxter International
BAX
$13.6B
| $273K | 0.01% |
7,970
| – | – |
|
100
PACS Group
PACS
$7.01B
| $225K | 0.01% |
20,000
| – | – |
|
Similar funds
Aaron Cowen's Q1 2025 Portfolio in Review
As of Q1 2025, Aaron Cowen held 112 positions worth $2.69B, down 8.2% from $2.93B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Aaron Cowen's Q1 2025 filing shows 16 new, 29 increased, 14 reduced and 12 closed positions. Its largest new stake was Home Depot: 97,571 shares worth $35.8M. The largest sale was Intra-Cellular Therapies Inc., an estimated $92M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.
- Aaron Cowen's largest Q1 2025 buy was Home Depot: 97,571 shares worth $35.8M.
- Aaron Cowen added most to Ultragenyx Pharmaceutical in Q1 2025, an estimated $36.3M increase.
- Aaron Cowen's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $92M.
- Aaron Cowen fully exited Starbucks in Q1 2025, selling an estimated $47M.
- Aaron Cowen's ten largest holdings make up 48% of its $2.69B portfolio in Q1 2025.
- Aaron Cowen opened 16 new positions and closed 12 in Q1 2025.
- Aaron Cowen's portfolio value fell 8.2% quarter-over-quarter to $2.69B.
Based on Suvretta Capital Management's 13F filing for Q1 2025, filed 15 May 2025.